Informação sobre produto
LDN-57444 is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and inhibits its activation. LDN-57444 is being developed for the treatment of squamous cell carcinoma, which is a type of skin cancer. The drug has been shown to inhibit tumor growth in animal models by inhibiting body formation, promoting autophagy, and reducing mitochondrial membrane potential. LDN-57444 has also been shown to inhibit the proliferation of human cancer cells in vitro and decrease cardiac arrhythmias. LDN-57444 binds to EGFR with a hydroxyl group on its structure that interacts with the EGFR's active site. This binding prevents EGFR from activating downstream signaling pathways, such as those involving phosphatidylinositol 3-kinase (PI3K) and Akt kinase, which are involved in cell proliferation and survival.
Propriedades químicas
Consulta técnica sobre: 3D-TBB46791 LDN-57444
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.
